CLIMB BIO, INC. Operating Income
CLIMB BIO, INC. (CLYM) reported Operating Income of -$15.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- CLIMB BIO, INC. operating income (loss) for the quarter ending 2026-06-30 was -$15.36M.
- CLIMB BIO, INC. operating income (loss) for the quarter ending 2026-03-31 was -$15.21M.
- CLIMB BIO, INC. operating income (loss) for the quarter ending 2025-12-31 was -$19.30M.
- CLIMB BIO, INC. operating income (loss) for the quarter ending 2025-09-30 was -$14.89M.
- CLIMB BIO, INC. operating income (loss) for fiscal 2025 was -$67.88M.
- CLIMB BIO, INC. operating income (loss) for fiscal 2024 was -$82.02M.
- CLIMB BIO, INC. operating income (loss) for fiscal 2023 was -$40.27M.
- CLIMB BIO, INC. operating income (loss) for fiscal 2022 was -$45.13M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.36M 10-Q · filed 2026-08-06 | -$30.57M 10-Q · filed 2026-08-06 | -$49.87M derived: sum of 3 quarters · filed 2026-08-06 | -$64.76M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$15.21M 10-Q · filed 2026-05-07 | -$34.51M derived: sum of 2 quarters · filed 2026-05-07 | -$49.40M derived: sum of 3 quarters · filed 2026-05-07 | -$60.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$19.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$34.19M derived: sum of 2 quarters · filed 2026-03-05 | -$44.87M derived: sum of 3 quarters · filed 2026-08-06 | -$67.88M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$14.89M 10-Q · filed 2025-11-06 | -$25.57M derived: sum of 2 quarters · filed 2026-08-06 | -$48.59M 10-Q · filed 2025-11-06 | -$59.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$10.68M 10-Q · filed 2026-08-06 | -$33.70M 10-Q · filed 2026-08-06 | -$44.61M derived: sum of 3 quarters · filed 2026-08-06 | -$56.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$23.02M 10-Q · filed 2026-05-07 | -$33.93M derived: sum of 2 quarters · filed 2026-05-07 | -$45.66M derived: sum of 3 quarters · filed 2026-05-07 | -$102.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$10.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$22.64M derived: sum of 2 quarters · filed 2026-03-05 | -$79.02M derived: sum of 3 quarters · filed 2026-03-05 | -$82.02M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$11.73M 10-Q · filed 2025-11-06 | -$68.10M derived: sum of 2 quarters · filed 2025-11-06 | -$71.11M 10-Q · filed 2025-11-06 | -$76.23M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$56.37M 10-Q · filed 2025-08-12 | -$59.38M 10-Q · filed 2025-08-12 | -$64.50M derived: sum of 3 quarters · filed 2025-08-12 | -$69.50M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$3.00M 10-Q · filed 2025-05-14 | -$8.13M derived: sum of 2 quarters · filed 2025-05-14 | -$13.13M derived: sum of 3 quarters · filed 2025-05-14 | -$19.84M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$5.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$10.12M derived: sum of 2 quarters · filed 2025-03-25 | -$16.84M derived: sum of 3 quarters · filed 2025-03-25 | -$40.27M 10-K · filed 2025-03-25 |
| 2023-09-30 | -$5.00M 10-Q · filed 2024-11-12 | -$11.71M derived: sum of 2 quarters · filed 2024-11-12 | -$35.15M 10-Q · filed 2024-11-12 | -$44.71M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$6.71M 10-Q · filed 2024-08-14 | -$30.15M 10-Q · filed 2024-08-14 | -$39.71M derived: sum of 3 quarters · filed 2024-08-14 | -$48.45M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$23.44M 10-Q · filed 2024-05-15 | -$32.99M derived: sum of 2 quarters · filed 2024-05-15 | -$41.74M derived: sum of 3 quarters · filed 2024-05-15 | -$55.44M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$9.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$18.30M derived: sum of 2 quarters · filed 2024-03-28 | -$32.00M derived: sum of 3 quarters · filed 2024-03-28 | -$45.13M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$8.75M 10-Q · filed 2023-11-14 | -$22.45M derived: sum of 2 quarters · filed 2023-11-14 | -$35.58M 10-Q · filed 2023-11-14 | -$46.28M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$13.70M 10-Q · filed 2023-08-10 | -$26.83M 10-Q · filed 2023-08-10 | -$37.54M derived: sum of 3 quarters · filed 2023-08-10 | -$46.92M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$13.13M 10-Q · filed 2023-05-11 | -$23.84M derived: sum of 2 quarters · filed 2023-05-11 | -$33.22M derived: sum of 3 quarters · filed 2023-05-11 | -$41.92M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$20.09M derived: sum of 2 quarters · filed 2023-03-06 | -$28.79M derived: sum of 3 quarters · filed 2023-03-06 | -$35.67M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$9.38M 10-Q · filed 2022-11-14 | -$18.09M derived: sum of 2 quarters · filed 2022-11-14 | -$24.97M 10-Q · filed 2022-11-14 | -$40.08M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$8.71M 10-Q · filed 2022-08-15 | -$15.59M 10-Q · filed 2022-08-15 | -$30.69M derived: sum of 3 quarters · filed 2022-08-15 | -$32.95M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$6.88M 10-Q · filed 2022-05-16 | -$21.99M derived: sum of 2 quarters · filed 2022-05-16 | -$24.25M derived: sum of 3 quarters · filed 2022-05-16 | -$25.85M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$15.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | -$17.37M derived: sum of 2 quarters · filed 2022-03-07 | -$18.97M derived: sum of 3 quarters · filed 2022-03-07 | -$20.93M 10-K · filed 2022-03-07 |
| 2020-09-30 | -$2.26M 10-Q · filed 2021-11-08 | -$3.87M derived: sum of 2 quarters · filed 2021-11-08 | -$5.82M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$1.61M 10-Q · filed 2021-09-13 | -$3.56M 10-Q · filed 2021-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |